Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice

BACKGROUND: Addition of docetaxel to androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been proved to be effective with an overall survival (OS) benefit in phase III clinical trials. The effectiveness of docetaxel with ADT in the general...

Descripción completa

Detalles Bibliográficos
Autores principales: Lendorf, Maria Elisabeth, Petersen, Peter Meidahl, Svendsen, Andrea Steen, Lindberg, Henriette, Brasso, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317901/
https://www.ncbi.nlm.nih.gov/pubmed/34337492
http://dx.doi.org/10.1016/j.euros.2020.12.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317901/
https://www.ncbi.nlm.nih.gov/pubmed/34337492
http://dx.doi.org/10.1016/j.euros.2020.12.006

Ejemplares similares